📰 Allogeneic News
Page 6 - Allogeneic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Allogeneic. Real-time updates on events, politics, business and more.
October 31, 2022
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on October 31,... | October 31, 2022
September 22, 2022
-- CK0803 are neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells -- CK0803 represents the company's fifth program to receive IND Clearance utilizing Cellenkos' proprietary CRANEtechnology HOUSTON, Sept. 22, 2022 /PRNewswire/ -- Cellenkos, Inc., a clinical stage biotech company that focuses on developing transformative cellular therapeutics for treatment of inflammatory disorders and autoimmune diseases, today announced that the U.S. Food and Drug Administrati...
August 5, 2022
Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma In July 2022, the U.S. Food and Drug... | August 5, 2022
July 15, 2022
PRESS RELEASE - INSIDE INFORMATION Recent medical publications provide new insights in timing and dynamics of fracture healing using early radiological...
June 17, 2022
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune... | June 17, 2022
June 3, 2022
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on May 31,... | June 3, 2022
May 5, 2022
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext...
April 19, 2022
Ncardia has launched a new business, Cellistic, to focus Ncardia's induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. This strategy expands on Ncardia's
April 19, 2022
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor T cell therapies for cancer, today announced the... | April 19, 2022
April 8, 2022
-- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- -- Data support an... | April 8, 2022